Roche buys antibody engineering firm led by ex-Serono team
This article was originally published in Scrip
Executive Summary
Roche is to pay $133.75m up front and up to $355m in additional milestone-dependent payments to acquire a bispecific antibody company set up by former managers from Merck Serono. Privately owned Dutalys of Austria has developed a novel class of fully human monoclonal antibodies called DutaMabs, designed to bind two antigens with high affinity and specificity.